<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00762996</url>
  </required_header>
  <id_info>
    <org_study_id>CR-0707</org_study_id>
    <nct_id>NCT00762996</nct_id>
  </id_info>
  <brief_title>The Clinical Evaluation of Two Daily Disposable Contact Lenses</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johnson &amp; Johnson Vision Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eurolens Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johnson &amp; Johnson Vision Care, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the clinical performance of two daily disposable
      contact lenses.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Distance Visual Acuity</measure>
    <time_frame>1 week</time_frame>
    <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lens Comfort</measure>
    <time_frame>1 week</time_frame>
    <description>A weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1=most negative response to 5=most positive was used to derive comfort outcomes. The analysis shows the difference in outcome between the test and control.&gt;0 = comfortable, &lt;0 = uncomfortable</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>etafilcon A/etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: etafilcon A, Period 2: etafilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>etafilcon A/omafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: etafilcon A, Period 2: omafilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omafilcon A/etafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: omafilcon A, Period 2: etafilcon A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>omafilcon A/omafilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period 1: omafilcon A, Period 2: omafilcon A</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>etafilcon A</intervention_name>
    <description>contact lens</description>
    <arm_group_label>etafilcon A/etafilcon A</arm_group_label>
    <arm_group_label>etafilcon A/omafilcon A</arm_group_label>
    <arm_group_label>omafilcon A/etafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>omafilcon A</intervention_name>
    <description>contact lens</description>
    <arm_group_label>etafilcon A/omafilcon A</arm_group_label>
    <arm_group_label>omafilcon A/etafilcon A</arm_group_label>
    <arm_group_label>omafilcon A/omafilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  They are of legal age (18 years) and capacity to volunteer.

          -  They understand their rights as a research subject and are willing to sign a Statement
             of Informed Consent.

          -  They are willing and able to follow the protocol.

          -  They would be expected to attain at least 6.9 (20/30) in each eye with the study
             lenses.

          -  They are able to wear contact lenses which have a back vertex power of -1.00 to
             -6.00DS.

          -  They have a maximum of 1.00D of refractive astigmatism (i.e. &lt; 1.00 DC).

          -  They have worn soft contact lenses within six months of starting the study.

        Exclusion Criteria:

          -  They have an ocular disorder which would normally contra-indicate contact lens wear.

          -  They have a systemic disorder which would normally contra-indicate contact lens wear.

          -  They are using any topical medication such as eye drops or ointment.

          -  They are aphakic.

          -  They have had corneal refractive surgery.

          -  They have any corneal distortion resulting from previous hard or rigid lens wear or
             has keratoconus.

          -  They are pregnant or lactating.

          -  They have grade 2 or greater of any of the following ocular surface signs: corneal
             edema, corneal vascularization, corneal staining, tarsal conjunctival changes or any
             other abnormality which would normally contraindicate contact lens wear.

          -  They have any infectious disease (e.g., hepatitis) or any immunosuppressive disease
             (e.g., HIV).

          -  They have diabetes.

          -  They are currently taking part in any other clinical study or research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Eurolens Research</name>
      <address>
        <city>Manchester</city>
        <zip>M60 1QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2008</study_first_submitted>
  <study_first_submitted_qc>September 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2008</study_first_posted>
  <results_first_submitted>October 24, 2008</results_first_submitted>
  <results_first_submitted_qc>May 1, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2009</results_first_posted>
  <last_update_submitted>May 5, 2015</last_update_submitted>
  <last_update_submitted_qc>May 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etafilcon A / Etafilcon A</title>
          <description>Period 1: etafilcon A, Period 2: etafilcon A</description>
        </group>
        <group group_id="P2">
          <title>Etafilcon A / Omafilcon A</title>
          <description>Period 1: etafilcon A, Period 2: omafilcon A</description>
        </group>
        <group group_id="P3">
          <title>Omafilcon A / Etafilcon A</title>
          <description>Period 1: omafilcon A, Period 2: etafilcon A</description>
        </group>
        <group group_id="P4">
          <title>Omafilcon A / Omafilcon A</title>
          <description>Period 1: omafilcon A, Period 2: omafilcon A</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period One</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>ineligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period Two</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Population</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Distance Visual Acuity</title>
        <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
          </group>
        </group_list>
        <measure>
          <title>Distance Visual Acuity</title>
          <description>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</description>
          <units>logMar</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03460" spread="0.007129"/>
                    <measurement group_id="O2" value="0.02931" spread="0.006666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: etafilcon A is greater than or equal to omafilcon A.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>margin +/- 0.5 logMar lines
The range of non-inferiority for this value is 0.50 thus +/- 0.50 is considered non-inferior to the 0.0 mark.
logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.005287</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.009760</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.01389</ci_lower_limit>
            <ci_upper_limit>0.2447</ci_upper_limit>
            <estimate_desc>logarithm of the minimum angle of resolution (logMar) ideal is 0.0 and represents 20/20 Snellen acuity. logMar values &gt; 0.00 indicate vision poorer than the ideal and values &lt;0.00 indicate vision greater than the ideal.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lens Comfort</title>
        <description>A weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1=most negative response to 5=most positive was used to derive comfort outcomes. The analysis shows the difference in outcome between the test and control.&gt;0 = comfortable, &lt;0 = uncomfortable</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Etafilcon A</title>
          </group>
          <group group_id="O2">
            <title>Omafilcon A</title>
          </group>
        </group_list>
        <measure>
          <title>Lens Comfort</title>
          <description>A weighted combined score calculated from individual comfort-related questions asked on a 1-5 scale: 1=most negative response to 5=most positive was used to derive comfort outcomes. The analysis shows the difference in outcome between the test and control.&gt;0 = comfortable, &lt;0 = uncomfortable</description>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3113" spread="0.1765"/>
                    <measurement group_id="O2" value="-0.1645" spread="0.2075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.4757</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2505</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.05563</ci_lower_limit>
            <ci_upper_limit>0.4757</ci_upper_limit>
            <estimate_desc>Mean difference is etafilcon A minus omafilcon A.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Etafilcon A / Etafilcon A</title>
          <description>Period 1: etafilcon A, Period 2: etafilcon A</description>
        </group>
        <group group_id="E2">
          <title>Etafilcon A / Omafilcon A</title>
          <description>Period 1: etafilcon A, Period 2: omafilcon A</description>
        </group>
        <group group_id="E3">
          <title>Omafilcon A / Etafilcon A</title>
          <description>Period 1: omafilcon A, Period 2: etafilcon A</description>
        </group>
        <group group_id="E4">
          <title>Omafilcon A / Omafilcon A</title>
          <description>Period 1: omafilcon A, Period 2: omafilcon A</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI may not publish, divulge, reveal, disclose, or use the data and or results of the study without prior written consent of Vistakon.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kurt Moody, OD, FAAO</name_or_title>
      <organization>Vistakon</organization>
      <phone>904-443-3088</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

